A conferência “Dosimetry in novel approaches in Radionuclide Therapy” será proferida pelo Prof. Manuel Bardiès, PhD,, pesquisador do Centre de Recherches en Cancérologie de Toulouse, UMR 1037, Institute Nationel de la Santé et de la Researche Medicate (INSERM), Université Paul Sabatier (UPS), Toulouse, France

O Prof. Bardiès é Meste e Doutor em Ciências e Técnicas de Engenharia Biomédica pela UPS (Toulouse III), Diretor de Pesquisas na Faculdade de Medicina de Toulouse. Desenvolve pesquisas em Dosimetria de Radiofármacos no INSERM desde 1991, em Nantes e Toulouse. Autor de 92 publicações, 1.360 citações, membro do Comitê de Dosimetria da Associação Européia de Medicina Nuclear (EANM). Publicou nos principais periódicos em Medicina: Physics in Medicine and Biology (10); European Journal of Nuclear Medicine (7); Cancer Biotherapy and Radiopharmaceuticals (6); Journal of Nuclear Medicine (4); Clinical Cancer Research (4)


Targeted Radionuclide Therapy (TRT) has been used for several decades for the treatment of thyroid pathologies (malignant or benign diseases).
Metaiodobenzilguanidine (mIBG) labelled with 131I is also used in a context of treatment of neuroendocrine tumours (neuroblastomas).
The generation of new categories of vectors has renewed the interest for TRT:
• Radioimmunotherapy has shown its potential in the treatment of non-Hodgkin lymphomas, with anti-CD20 labelled with 131I (Bexxar™) or 90Y (Zevalin™). New monoclonal antibodies are currently being investigated for the treatment of hematologic diseases or prostate cancer.
• Peptide Receptor Radionuclide Therapy (PRRT) is also a recent approach to the treatment of neuroendocrine tumours, with somatostatin analogues labelled with 90Y or 177Lu.
• Another fast growing domain is that of radioembolization, where 90Y radioactive microspheres of resin or glass are administered for the treatment of liver cancers or metastases.
• The palliative treatment of bone metastases with 223Ra (Xofigo™) is also attracting a lot of interest.
These new therapeutic modalities are usually administered as a “radioactive chemotherapy”, i.e. activity administered is fixed (“one size fits all”), or modulated with patient’s weight, body surface area or equivalent.
As TRT efficacy relies of the toxic effect of ionizing radiations, patient-specific dosimetry is essential to monitor the treatment that is delivered, but also to optimize the treatment by calculating the activity that needs to be administered of the basis of the absorbed dose delivered to cancer targets or to critical organs/tissues.
Radiopharmaceutical dosimetry has seen major improvements in the last decade, from model-based computations to patient-specific 3D assessment of the absorbed dose. The absorbed dose – effect relationship has been evidenced in most treatment modalities – basically as long as a relevant methodology could be implemented. It is time to move away from the “radioactive chemotherapy” paradigm to fully exploit the potential of targeted radionuclide therapy.